A5034997068- Transplantation: Methods and Outcomes
- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Congenital Heart Disease Studies
- Viral Infections and Immunology Research
- Polyomavirus and related diseases
- Cancer Genomics and Diagnostics
- Cardiomyopathy and Myosin Studies
- Viral-associated cancers and disorders
- Cardiovascular Issues in Pregnancy
- Cardiac Valve Diseases and Treatments
- Moyamoya disease diagnosis and treatment
- Lymphatic Disorders and Treatments
- Vascular anomalies and interventions
- Pneumocystis jirovecii pneumonia detection and treatment
- Cardiac pacing and defibrillation studies
- Prenatal Screening and Diagnostics
- Cardiovascular Effects of Exercise
- RNA Interference and Gene Delivery
- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Parvovirus B19 Infection Studies
- Neurological Complications and Syndromes
Phoenix Children's Hospital
2015-2024
Children's Center
2023
American Association of Nurse Practitioners
2022
Children's Hospital of Wisconsin
2008-2020
Medical College of Wisconsin
2006-2020
University of Arizona
2019
In-Q-Tel
2013
Boston Children's Hospital
2009-2010
University of Wisconsin–Milwaukee
2005
Penn State Milton S. Hershey Medical Center
1999
BACKGROUND Posttransplantation lymphoproliferative disorders (PT-LPDs) are a well-known complication of immunosuppression associated with solid organ transplantation. The clinical course PT-LPDs is unpredictable; some patients experience regression all lesions reduction in immunosuppression, whereas other patients, despite chemotherapy, radiation therapy, or surgery, rapidly die their disease. In this study, the authors attempted to establish whether previously described morphologic and...
Abstract: Heart transplantation in the setting of human leukocyte antigen (HLA) sensitization is challenging, as a time‐consuming prospective crossmatch (XM) may be required, severely limiting number potential donors. We evaluated ‘virtual XM’, defining positive virtual XM presence recipient pre‐formed anti‐HLA antibodies to donor HLA type, and compared standard direct XM. Bead‐based flow cytometric analysis was used identify antibody (Ab) present child listed for heart transplantation....
Abstract: Background: HLA antibody sensitization is a risk factor for morbidity and mortality following heart transplantation. We previously reported the results of our in vitro study demonstrating predictive value Virtual Crossmatch (VXM) have since applied it clinically sensitized children listed transplant at center. The VXM utilizes specific screening via flow cytometry to predict acute incompatibility. This review examines effect on wait times outcomes. Methods: population included all...
It is now recognized that a majority of single ventricle patients, those with functionally univentricular hearts, who have survived palliative cavopulmonary connection will experience circulatory failure and end-organ dysfunction due to intrinsic inadequacies circulation supported by ventricle. Thus, there are an increasing number patients functional ventricles presenting failing circulations may benefit from mechanical support (MCS). The paucity MCS in this population, even at high volume...
We assessed the association of socioeconomic (SE) position with graft loss in a multicenter cohort pediatric heart transplant (HT) recipients. extracted six SE variables from US Census 2000 database for neighborhood residence 490 children who underwent their primary HT at participating centers. A composite score was derived each child and four groups (quartiles) compared (death or retransplant). Graft occurred 152 (122 deaths, 30 In adjusted analysis, during first posttransplant year had...
Abstract Background Listed pediatric heart transplant patients have the highest solid‐organ waitlist mortality rate. The donor‐recipient body weight ( DRBW ) ratio is clinical standard for allograft size matching but may unnecessarily limit a patient's donor pool. To overcome limitations, two methods of performing virtual fit assessments were developed that account patient‐specific nuances. Method 1 uses an total cardiac volume TCV prediction model informed by patient data wherein matched...
The aims of the study were to assess performance a clinically available cell-free DNA (cfDNA) assay in large cohort pediatric and adult heart transplant recipients evaluate at specific cut points detection rejection.
Abstract Children with end‐stage cardiac failure are at risk of HA and PG . The effects these factors on post‐transplant outcome not well defined. Using the PHTS database, albumin growth data from pediatric heart transplant patients 12/1999 to 12/2009 were analyzed for effect mortality. Covariables examined determine whether mortality listing transplant. had higher waitlist (15.81% vs. 10.59%, p = 0.015) an OR 1.59 (95% CI 1.09–2.30). Survival was worse (p ≤ 0.01 0.026). Infants congenital...
Abstract Our aim is to develop and validate an accurate method for estimating TCV using standard echocardiographic imaging that can be easily employed aid in donor–recipient size matching pediatric heart transplantation. Thirty patients who underwent Echo cardiac magnetic resonance ( cMRI ) were identified. was measured on . determined echocardiographically by two methods: a volume measurement the modified Simpson's four‐chamber view of heart; calculated which assumed true‐elliptical shape...
Our objective is to describe the use of a ventricular assist device (VAD) in single-ventricle patients with circulatory failure following superior cavopulmonary anastomosis (SCPA). We performed retrospective chart review all supported VAD SCPA. Implantation techniques, physiologic parameters while supported, medical and surgical interventions postimplant, outcomes were reviewed. Four an EXCOR Pediatric (Berlin Heart Inc., The Woodlands, TX, USA) SCPA for median duration 10.5 days (range...
Abstract Heart transplantation is a well‐established therapy for end‐stage heart failure in children and young adults. The highest risk of graft loss occurs the first 60 days post‐transplant. Donor fraction cell‐free DNA highly sensitive marker injury. Changes levels have not previously been studied depth patients early after transplant. A prospective study was conducted among transplant recipients at single pediatric center. Blood samples were collected from adult three time points within...
Elevated total cell-free DNA (TCF) concentration has been associated with critical illness in adults and elevated donor fraction (DF), the ratio of specific to present recipient's plasma, is rejection following cardiac transplantation. This study investigates relationships between TCF clinical outcomes after heart transplantation.A prospective, blinded, observational 87 transplantation recipients was performed. Samples were collected at transplantation, prior endomyocardial biopsy, during...